Funding Daily Summary
Funding Daily Summary: What Happened on October 12, 2026
Desentum raises €28 million for three allergy programs
The Finnish company’s lead candidate is in Phase 2, with results expected before the end of 2026.
Today in brief
Desentum raised €28 million in an oversubscribed equity round to support three allergy immunotherapy programs.1 The ongoing Phase 2 trial of its lead candidate, DM-101PX, is testing efficacy in about 100 patients, with results expected before year-end.1
Desentum raises €28 million to advance allergy programs
The equity financing will fund work on three allergy immunotherapy programs. Springvest arranged the round.1 Springvest has arranged €54 million for Desentum in total and is also a major shareholder.1
In a randomized, placebo-controlled Phase 1 study of 30 adults, 24 received DM-101PX. The candidate produced a strong antibody response after 10 weekly injections.1 Treatment-related adverse events occurred in 22 treated participants. All were mild or moderate, mostly injection-site reactions.1 Five participants had systemic allergic reactions, and no serious adverse events were reported.1 The ongoing Phase 2 BASIT study is assessing efficacy in about 100 patients. Results are expected before the end of 2026.1